Skip to main content

MoneyWorks4Me

Biocon gets USFDA’s nod for Pebrilzo

16 Nov 2026 Evaluate

Biocon has received the U.S. Food and Drug Administration’s (USFDA) approval for Pebrilzo (pertuzumab-qcay), a biosimilar of the reference product Perjeta (pertuzumab). Pebrilzo is a monoclonal antibody used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer cells. The USFDA approval further strengthens the company’s oncology portfolio. Moreover, the company entered a global settlement and license agreement with Genentech securing the earliest licensed launch date for PEBRILZO in the United States in Q3 of calendar year 2028.

Earlier, in September, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had given a positive opinion recommending the granting of a marketing authorization for Biocon’s Pertuzumab biosimilar as 420 mg/14 mL concentrate solution for infusion, under the brand name Pebrilzo, for the treatment of HER2-positive breast cancer across multiple disease stages in Europe.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Peers
Company Name CMP
Sun Pharma. Inds. 1873.80
Dr. Reddys Labs. 1384.35
Cipla 1387.90
Lupin 1948.20
Zydus Lifesciences 1201.35
View more..